LMR Partners LLP Makes New $218,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

LMR Partners LLP purchased a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the third quarter, HoldingsChannel reports. The institutional investor purchased 100,000 shares of the company’s stock, valued at approximately $218,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Palumbo Wealth Management LLC acquired a new stake in Ventyx Biosciences in the 3rd quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after acquiring an additional 5,310 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Ventyx Biosciences by 149.8% in the third quarter. SG Americas Securities LLC now owns 34,670 shares of the company’s stock valued at $76,000 after purchasing an additional 20,792 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Ventyx Biosciences in the second quarter worth $154,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in Ventyx Biosciences by 165.8% during the second quarter. Cubist Systematic Strategies LLC now owns 149,500 shares of the company’s stock worth $345,000 after purchasing an additional 93,247 shares during the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $1.72 on Thursday. Ventyx Biosciences, Inc. has a 52 week low of $1.72 and a 52 week high of $11.48. The stock has a market capitalization of $121.62 million, a P/E ratio of -0.75 and a beta of 0.37. The stock has a 50-day simple moving average of $2.21 and a 200 day simple moving average of $2.70.

Analyst Ratings Changes

Several brokerages have issued reports on VTYX. Canaccord Genuity Group lowered their price target on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Wells Fargo & Company reduced their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. HC Wainwright restated a “neutral” rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research note on Monday, November 11th. Finally, Oppenheimer reiterated an “outperform” rating and set a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.